The growth of benign prostatic hyperplasia treatment market is driven by the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment.
The global benign
prostatic hyperplasia treatment market is projected to reach USD
14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021
to 2026.
Download PDF Brochure:
- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374
Market Segmentation :
Based
on the type, the BPH treatment market is segmented into drug treatment and
surgical treatment. Drug treatment is the largest and the fastest-growing
segment in this market. This can primarily be attributed to the use of
medications as the first line of treatment among men with mild to moderate
symptoms of BPH.
Based on the end
user, the market is segmented into home healthcare and hospitals & clinics.
In 2019, home healthcare accounted for the largest share of this market, as
most patients are prescribed medications over surgery. Patients are also
advised to continue taking medications for a few weeks post-surgery and may
even require catheters for a few days. As a result, the emphasis in his market
is skewed toward home healthcare over hospital care.
Regional
Analysis:-
On
the basis of region, the benign prostatic hyperplasia treatment market is
segmented into North America, Europe, Asia Pacific, and the Rest of the World.
In 2019, North America commanded the largest share of the benign prostatic
hyperplasia treatment market. The large share of this market segment can be
attributed to the rising geriatric and obese population and the
availability of research funding are the major factors driving the market
growth. Initiatives by key players are also expected to contribute to the
market.
Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374
Top Key
Players -
Key
players in this market can explore the possibilities of expanding to the
economies of the Asian countries such as China, Japan, Australia, and the
Association of Southeast Asian Nations (ASEAN) countries, due to presence
of a large geriatric and target patient population and the improving healthcare
infrastructure in several APAC countries.
No comments:
Post a Comment